The Scripps Research Institute has identified new baloxavir analogues and their prodrugs acting as new influenza cap-dependent endonuclease (CEN) inhibitors potentially useful for the treatment of influenza viral infections.
SARS-CoV-2 utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry and triggers ACE2 ectodomain shedding, which results in elevated vasoconstrictor angiotensin II (Ang-II) while depleting the protective Ang-(1-7). This effect can lead to acute respiratory distress syndrome, hypertension, acute kidney injury and organ damage.
Amending his previous two-year-renewal of the standard charter for the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP), Health and Human Services Secretary Robert Kennedy made monitoring adverse vaccine events a primary function of the committee and expanded its liaison membership to include organizations that have challenged vaccine safety.>
Invivyd Inc. has announced the discovery and advancement of VMS-063, a novel monoclonal antibody candidate for the treatment and prevention of measles.
Huawu Biopharmaceutical Technology (Hubei) Co. Ltd. has divulged new viral replication inhibitors potentially useful for the treatment of dengue and yellow fever virus infections.
Don’t like a court order? Sidestep it. That seems to be the idea behind U.S. Health and Human Services Secretary Robert Kennedy’s latest changes to his renewal of the charter for the CDC’s Advisory Committee on Immunization Practices (ACIP).
In previous work, researchers from the University of Georgia developed liposomes loaded with antifungal drugs and coated with the carbohydrate recognition domains of mouse dectin-1 and/or dectin-2, called Dectisomes. The murine Dectisomes efficiently bound and killed pathogenic fungi in vitro and in mouse disease models. In a new study, the team aimed to explore how to potentially move Dectisomes into the clinic with human dectin orthologues.
Wuhan Xirui Pharmaceutical Technology Co. Ltd. has synthesized new amphotericin B amide derivatives that are potentially useful for the treatment of fungal infection.
Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.
At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.
RSS
